DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring  MD  20993

NDA 22334/S-32
NDA 203985/S-10

SUPPLEMENT APPROVAL
FULFILLMENT OF POSTMARKETING REQUIREMENTS

Novartis Pharmaceuticals Corporation
Attention: Rose Gao
Director, Oncology Drug Regulatory Affairs
One Health Plaza
Building 315, 4th Floor
East Hanover, NJ 07936

Dear Ms. Gao:

Please refer to your supplemental New Drug Applications (sNDAs) dated March 31, 2015, received March 31, 2015, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA), for AFINITOR® (everolimus) tablets for oral administration and AFINITOR® DISPERZ (everolimus tablets for oral suspension).

These Prior Approval supplemental new drug applications confirm the clinical benefit of AFINITOR and AFINITOR DISPERZ for the treatment of pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected, approved on October 29, 2010, for AFINITOR and approved on August 29, 2012, for AFINITOR DISPERZ under the provisions of 21 CFR 314.510. The INDICATIONS AND USAGE, Subependymal Giant Cell Astrocytoma (SEGA) with Tuberous Sclerosis Complex (TSC) subsection has been revised to remove the following language (italicized): The effectiveness of AFINITOR Tablets and AFINITOR DISPERZ is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in disease-related symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. In addition, the ADVERSE REACTIONS, USE IN SPECIFIC POPULATIONS, Pediatric Use, and CLINICAL STUDIES sections of labeling have been revised with the results of the clinical trial verifying the clinical benefit of AFINITOR and AFINITOR DISPERZ in this population.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert and text for the patient package insert, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

SUBPART H FULFILLED

We approved NDA 22334/S-6 and NDA 203985 under the regulations at 21 CFR 314 Subpart H for accelerated approval of new drugs for serious or life-threatening illnesses. Approval of NDA 22334/S-32 and NDA 203985/S-10 fulfills the below post marketing requirement (PMR #1700-1) made under 21 CFR 314.510:
PMR 1700-1:

Submit the final report (at least 4 years of follow-up) and datasets from M2301, a randomized, double-blind, placebo-controlled, multi-center Phase 3 trial evaluating treatment with everolimus versus placebo in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

FULFILLMENT OF POSTMARKETING REQUIREMENTS

We have also received your submissions dated March 31, 2015, containing the final reports for the following postmarketing requirement listed in the October 29, 2010, approval letter for NDA 22334/S-6 and the August 29, 2012, approval letter for NDA 203985.

PMR 1700-3:

To evaluate the potential for serious risk of adverse long-term effects of Afinitor (everolimus) on growth for pediatric patients, submit long-term follow-up data on patients enrolled on M2301, a randomized, double-blind, placebo-controlled, multi-center phase 3 trial evaluating treatment with Afinitor (everolimus) versus placebo in patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).

We have reviewed your submission and conclude that the above requirement was fulfilled. You are no longer required to report on this requirement.

We remind you that there are postmarketing requirements listed in the April 26, 2012, and July 20, 2012, approval letters that are still open.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory...
comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: [http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf](http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf)).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf). Information and Instructions for completing the form can be found at [http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf](http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf). For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Sharon Sickafuse, Senior Regulatory Health Project Manager, at (301) 796-2320.

Sincerely,

{See appended electronic signature page}

Patricia Keegan, M.D.  
Director  
Division of Oncology Products 2  
Office of Hematology and Oncology Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOSEPH E GOOTENBERG on behalf of PATRICIA KEEGAN
01/29/2016